NCT00347841已完成4 期
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •· Male or female > 18 years of age
- •Documented low-responder to latanoprost therapy as delineated in the outline above.
- •Diagnosis of open-angle glaucoma or ocular hypertension
- •Ability to provide informed consent and likely to complete all study visits
排除标准
- •· Known contraindication to bimatoprost or any component of any study medication
- •Uncontrolled systemic disease
- •Active ocular disease other than glaucoma or ocular hypertension
- •Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
- •History of intraocular surgery within the last 3 months
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)Ocular HypertensionGlaucoma, Open-AngleNCT01594970Allergan800
已完成
4 期
24-hour IOP-lowering Effect of 0.01% BimatoprostOcular HypertensionIntraocular PressureGlaucomaNCT01271686University of California, San Diego16
已完成
4 期
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular HypertensionGlaucomaNCT00348023Innovative Medical
已完成
不适用
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01646151Allergan2,580
已完成
不适用
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)Ocular HypertensionOpen-Angle GlaucomaNCT00716742Allergan1,099